TYRA vs. BCYC, SAVA, ARQT, OCUL, INVA, LQDA, IRWD, CNTA, OPK, and ETNB
Should you be buying Tyra Biosciences stock or one of its competitors? The main competitors of Tyra Biosciences include Bicycle Therapeutics (BCYC), Cassava Sciences (SAVA), Arcutis Biotherapeutics (ARQT), Ocular Therapeutix (OCUL), Innoviva (INVA), Liquidia (LQDA), Ironwood Pharmaceuticals (IRWD), Centessa Pharmaceuticals (CNTA), OPKO Health (OPK), and 89bio (ETNB). These companies are all part of the "pharmaceutical preparations" industry.
Bicycle Therapeutics (NASDAQ:BCYC) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.
Tyra Biosciences has a net margin of 0.00% compared to Tyra Biosciences' net margin of -404.14%. Bicycle Therapeutics' return on equity of -28.61% beat Tyra Biosciences' return on equity.
Bicycle Therapeutics received 102 more outperform votes than Tyra Biosciences when rated by MarketBeat users. Likewise, 68.57% of users gave Bicycle Therapeutics an outperform vote while only 62.07% of users gave Tyra Biosciences an outperform vote.
In the previous week, Tyra Biosciences had 13 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 19 mentions for Tyra Biosciences and 6 mentions for Bicycle Therapeutics. Tyra Biosciences' average media sentiment score of 0.93 beat Bicycle Therapeutics' score of 0.74 indicating that Bicycle Therapeutics is being referred to more favorably in the media.
Bicycle Therapeutics presently has a consensus target price of $46.86, indicating a potential upside of 111.26%. Tyra Biosciences has a consensus target price of $23.50, indicating a potential upside of 23.04%. Given Tyra Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Bicycle Therapeutics is more favorable than Tyra Biosciences.
Tyra Biosciences has lower revenue, but higher earnings than Bicycle Therapeutics. Tyra Biosciences is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.
Bicycle Therapeutics has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, Tyra Biosciences has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.
86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 8.5% of Bicycle Therapeutics shares are held by company insiders. Comparatively, 15.4% of Tyra Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Bicycle Therapeutics beats Tyra Biosciences on 9 of the 17 factors compared between the two stocks.
Get Tyra Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for TYRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tyra Biosciences Competitors List
Related Companies and Tools
